Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
odronextamab + lenalidomide
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of odronextamab, a bispecific monoclonal antibody targeting CD20 and CD3, and lenalidomide, an immunomodulatory small molecule. Odronextamab engages both T cells (via CD3) and malignant B cells (via CD20) to induce T cell-mediated cytotoxicity against B-cell non-Hodgkin lymphoma. Lenalidomide modulates the immune response and exhibits antineoplastic activity through cereblon-dependent mechanisms, enhancing cytotoxic immune cell activity and inhibiting tumor-promoting microenvironment interactions. The combination is under clinical investigation, primarily for relapsed/refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL), subtypes of non-Hodgkin lymphoma, and the regimen is considered first-in-human as a combination.
- Other names
- odronextamablenalidomide
02
Targets
Beyond the preview
Go deeper on odronextamab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on odronextamab + lenalidomide.